UK markets closed
  • NIKKEI 225

    26,215.79
    +278.59 (+1.07%)
     
  • HANG SENG

    17,079.51
    -143.29 (-0.83%)
     
  • CRUDE OIL

    83.34
    +3.85 (+4.84%)
     
  • GOLD FUTURES

    1,708.60
    +36.60 (+2.19%)
     
  • DOW

    29,490.89
    +765.38 (+2.66%)
     
  • BTC-GBP

    17,292.43
    +277.66 (+1.63%)
     
  • CMC Crypto 200

    444.05
    +8.70 (+2.00%)
     
  • Nasdaq

    10,815.43
    +239.83 (+2.27%)
     
  • ^FTAS

    3,773.80
    +10.32 (+0.27%)
     

Macular Degeneration Treatment Global Market Report 2022: Continued Development of Advanced Therapies Presents Opportunities

·4-min read
Company Logo
Company Logo

Dublin, Sept. 08, 2022 (GLOBE NEWSWIRE) -- The "Macular Degeneration Treatment Market Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

The global macular degeneration treatment market is expected to grow from $7.55 billion in 2021 to $8.08 billion in 2022 at a compound annual growth rate (CAGR) of 7.04%. The market is expected to reach $10.65 billion in 2026 at a CAGR of 7.15%.

In 2021, North America will be the largest region in the macular degeneration treatment market. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The increasing burden of retinal disorders is expected to propel the growth of the macular degeneration treatment market. Retinal disorders affect the vital tissue and affect the way individuals process visual information, leading to distorted or absent vision. According to a study done in Tanzania in 2020 about the prevalence of retinal diseases and associated risk factors, out of 1,007 people, the prevalence of vitreoretinal disorders was 22.8% (230/1,007).

The study was conducted by OSLI Retina, which focuses solely on retinal diseases, surgery, and pharmacotherapy. The leading retinal diseases were age-related hypertensive macular scars (2.7%), retinopathy (4.5%), and degeneration (7.0%). According to the American Academy of Opthalmology, in 2050, an estimated 7.32 million people in the United States will have primary open-angle glaucoma, with the highest numbers among populations aged 70 to 79 years (32%), women (50%), and Hispanics (50%). The largest demographic group is Hispanic men. Therefore, the increasing burden of retinal disorders is driving the growth of the macular degeneration treatment market.

The development of advanced therapies is a key trend gaining popularity in the macular degeneration treatment market. Advanced therapy, including gene therapy, for the treatment of disease has seen development in recent years, particularly within the world of inherited retinal disease.

For instance, in the year 2019, Spark Therapeutics, a USA-based gene therapy treatment company, developed Luxturna, which is a therapy designed to treat patients with mutations on a gene called RPE65, which encodes a retinal protein necessary for the eye in order to respond to light.

In September 2021, Novartis, a Swiss-based pharmaceutical company, acquired Arctos Medical for an undisclosed amount. The acquisition is expected to allow Novartis to find treatments for patients with vision loss and leverage the potential of optogenetics as the basis of successful therapeutics. Arctos Medical is a Switzerland-based developer of smart medical devices and gene therapy approaches for ophthalmological diseases for treating blindness.

The countries covered in the Macular Degeneration Treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Scope
Markets Covered:1) By Stage of Disease: Early-Stage AMD; Intermediate AMD; Late-Stage AMD
2) By End User: Ambulatory Surgical Centers; Ophthalmic Clinics; Hospitals
3) By Route of Administration: Oral; Injectable; Others
4) By Types: Wet Macular Degeneration, Dry Macular Degeneration

Key Topics Covered:

1. Executive Summary

2. Macular Degeneration Treatment Market Characteristics

3. Macular Degeneration Treatment Market Trends And Strategies

4. Impact Of COVID-19 On Macular Degeneration Treatment

5. Macular Degeneration Treatment Market Size And Growth

6. Macular Degeneration Treatment Market Segmentation

7. Macular Degeneration Treatment Market Regional And Country Analysis

8. Asia-Pacific Macular Degeneration Treatment Market

9. China Macular Degeneration Treatment Market

10. India Macular Degeneration Treatment Market

11. Japan Macular Degeneration Treatment Market

12. Australia Macular Degeneration Treatment Market

13. Indonesia Macular Degeneration Treatment Market

14. South Korea Macular Degeneration Treatment Market

15. Western Europe Macular Degeneration Treatment Market

16. UK Macular Degeneration Treatment Market

17. Germany Macular Degeneration Treatment Market

18. France Macular Degeneration Treatment Market

19. Eastern Europe Macular Degeneration Treatment Market

20. Russia Macular Degeneration Treatment Market

21. North America Macular Degeneration Treatment Market

22. USA Macular Degeneration Treatment Market

23. South America Macular Degeneration Treatment Market

24. Brazil Macular Degeneration Treatment Market

25. Middle East Macular Degeneration Treatment Market

26. Africa Macular Degeneration Treatment Market

27. Macular Degeneration Treatment Market Competitive Landscape And Company Profiles

28. Key Mergers And Acquisitions In The Macular Degeneration Treatment Market

29. Macular Degeneration Treatment Market Future Outlook and Potential Analysis

30. Appendix

Companies Mentioned

  • Novartis AG

  • Bausch Health Companies Inc.

  • Regenxbio Inc.

  • F Hoffmann-La Roche Ltd

  • Regeneron Pharmaceuticals Inc.

  • GlaxoSmithKline plc

  • Bayer AG

  • Neurotech Pharmaceuticals Inc.

  • Ophthotech Corporation

  • Stemcells Inc.

  • Pfizer Inc.

  • Santen Pharmaceuticals

  • Alimera Sciences Inc.

  • Aerie Pharmaceutical Inc.

  • Panoptica

  • Allergan Inc.

  • Valeant Pharmaceuticals

  • Rxi Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/qi0w7a

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900